The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells
J Neukirchen, A Meier, A Rohrbeck… - Cancer gene …, 2007 - nature.com
In this report, the effects of a combined treatment with the proteasome inhibitor bortezomib
and either a recombinant adeno-associated virus type 2 (rAAV-2)-mediated p53 gene …
and either a recombinant adeno-associated virus type 2 (rAAV-2)-mediated p53 gene …
Bortezomib Has Anti-Proliferative and Apoptotic Effects Against CML Stem Cells, Including the Quiescent Population.
N Heaney, F Pellicano, L Crawford, S Irvine… - 2007 - ashpublications.org
CML is a disease of the haemopoietic stem cell (HSC) caused by the constitutively active
tyrosine kinase Bcr-Abl. The current first-line therapy for CML is imatinib (IM), a tyrosine …
tyrosine kinase Bcr-Abl. The current first-line therapy for CML is imatinib (IM), a tyrosine …
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor …
C Yu, M Rahmani, P Dent, S Grant - Experimental cell research, 2004 - Elsevier
The hierarchy of events accompanying induction of apoptosis by the proteasome inhibitor
Bortezomib was investigated in Jurkat lymphoblastic and U937 myelomonocytic leukemia …
Bortezomib was investigated in Jurkat lymphoblastic and U937 myelomonocytic leukemia …
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
J Codony-Servat, MA Tapia, M Bosch, C Oliva… - Molecular cancer …, 2006 - AACR
The cellular and molecular effects of the proteasome inhibitor bortezomib on breast cancer
cells are as yet poorly characterized. Here, in a panel of six breast cancer cell lines …
cells are as yet poorly characterized. Here, in a panel of six breast cancer cell lines …
TNF potentiates anticancer activity of bortezomib (Velcade®) through reduced expression of proteasome subunits and dysregulation of unfolded protein response
D Nowis, EJ McConnell, L Dierlam… - … journal of cancer, 2007 - Wiley Online Library
Bortezomib (Velcade®) exploits proteasome inhibition as a unique mechanism of anticancer
activity. The effectiveness of bortezomib is, however, limited, therefore, the search for …
activity. The effectiveness of bortezomib is, however, limited, therefore, the search for …
[HTML][HTML] Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib.
E Suzuki, S Demo, S Arastu-Kapur, CJ Kirk… - Blood, 2009 - Elsevier
Abstract Abstract 2852 Poster Board II-828 Introduction: Carfilzomib (CFZ) is a selective and
irreversible proteasome inhibitor that induces anti-tumor activity through inhibition of the …
irreversible proteasome inhibitor that induces anti-tumor activity through inhibition of the …
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia
S Ruiz, Y Krupnik, M Keating, J Chandra… - Molecular cancer …, 2006 - AACR
Proteasome inhibitors are potent inducers of apoptosis in isolated lymphocytes from patients
with chronic lymphocytic leukemia (CLL). However, the reversible proteasome inhibitor …
with chronic lymphocytic leukemia (CLL). However, the reversible proteasome inhibitor …
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells
O Fuchs, D Provaznikova, I Marinov… - … Current Drug Targets …, 2009 - ingentaconnect.com
New chemotherapeutic agents are still required to further optimise treatment of leukemia
patients. Proteasome inhibition by bortezomib, PR-171 (carfilzomib) and NPI-0052 …
patients. Proteasome inhibition by bortezomib, PR-171 (carfilzomib) and NPI-0052 …
Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB
L Bastian, J Hof, M Pfau, I Fichtner, C Eckert… - Clinical Cancer …, 2013 - AACR
Purpose: Relapse of disease and subsequent resistance to established therapies remains a
major challenge in the treatment of childhood B-cell precursor acute lymphoblastic leukemia …
major challenge in the treatment of childhood B-cell precursor acute lymphoblastic leukemia …
Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells
Inhibition of the proteasome has emerged as a clinically effective anticancer therapeutic
approach in recent years. Bortezomib (Velcade®) showed extremely high potency against a …
approach in recent years. Bortezomib (Velcade®) showed extremely high potency against a …